GCP ClinPlus offers comprehensive clinical trial services across the full lifecycle of drug development in rheumatology, from Phase I–III studies to post-marketing research. With extensive expertise in autoimmune and inflammatory disorders, we support trials in ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, psoriasis, inflammatory bowel disease (IBD), and more. Our integrated approach ensures scientific rigor, regulatory compliance, and operational excellence.

Delivering What Matters to Biopharma

With deep scientific grounding and rich operational experience, GCP ClinPlus has built a reputation as a trusted Immunology CRO in China partner in rheumatology clinical research.

Delivering What Matters to Biopharma

We specialize in autoimmune and chronic inflammatory diseases, supporting the development of innovative therapies that require precise efficacy evaluation and long-term safety monitoring.

Our key strengths include:

Proven clinical execution capabilities across all phases, ensuring accurate data capture and risk control, critical for regulatory approval

Scientific leadership informed by the latest immunology research, enabling insightful protocol development and targeted patient recruitment

Extensive investigator and KOL network, encompassing leading academic and clinical institutions both in China and internationally

Strict compliance with regulatory and ethical standards, ensuring transparency, patient safety, and data integrity throughout the trial process

From mechanism-driven Phase I trials to large-scale registration studies and post-market surveillance, GCP ClinPlus provides agile, end-to-end solutions that accelerate development and bring impactful therapies to patients suffering from complex immune-related diseases.

or more information about China Clinical Trial RA and drug development trials, please feel free to contact us!